uniQure N.V. (QURE)
NASDAQ:QURE
QURE Stock Chart & Stats
$17.16
-$1.39(-7.88%)
At close: 4:00 PM EST
$17.16
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$7.76 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)4.73M
Market Cap
$1.06B
Enterprise Value$1.51B
Total Cash (Recent Filing)$622.54M
Total Debt (Recent Filing)$536.59M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 12, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding61,603,770
10 Day Avg. Volume1,966,010
30 Day Avg. Volume4,733,432
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue94.02
Enterprise Value/Gross Profit132.27
Enterprise Value/Ebitda-10.63
Forecast
1Y Price Target
$32.00Price Target Upside86.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.61
Revenue Forecast (FY)$34.70M
Bulls Say, Bears Say
Bulls Say
AMT-130 Clinical DurabilityLong-term clinical signals for AMT-130 are regarded as one of the strongest datasets in Huntington's disease and could support negotiation of an alternative regulatory path if durability is confirmed.
Fabry Program OptionalityAMT-191 produced durable, dose-dependent increases in the therapeutic enzyme and enabled several patients to stop enzyme replacement therapy, offering meaningful upside optionality beyond the lead program.
Regulatory OutlookChange in regulatory leadership and a planned Type B meeting have prompted analyst re-rating of the likelihood for a more constructive dialogue with regulators on AMT-130, potentially clarifying the approval pathway.
Bears Say
Insufficient Early-stage EvidenceRegulators view early-stage data compared with external controls as insufficient to support a filing, creating major uncertainty unless new, more convincing confirmatory evidence is generated.
Safety And Dosing RisksDose-limiting toxicities, including liver enzyme elevations that prompted dosing pauses, raise concerns about dose selection, patient safety and the feasibility of larger pivotal studies.
Sham-controlled Trial RequirementFDA preference for a prospective, randomized, double-blind sham surgery-controlled trial would substantially increase trial complexity, extend development timelines and require significant additional capital.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $7.76 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $1.06B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is May 12, 2026 which is in 37 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Mar 02, 2026. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.914 by $0.344.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.87.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 61,603,770 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.914. Following the earnings report the stock price went down -32.821%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (86.48% Upside)
$32.00 (86.48% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 245.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.58%
12-Months-Change
Fundamentals
Return on Equity
-174.03%
Trailing 12-Months
Asset Growth
48.22%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated major positive clinical advances (notably strong 3‑year AMT‑130 efficacy, supportive Fabry and TLE data) and a strengthened balance sheet, but these were tempered by significant regulatory resistance from the FDA (recommendation for a sham‑controlled Phase III), safety‑related pauses/holds in two programs (AMT‑191 dosing pause and AMT‑162 hold), and a substantial year‑over‑year revenue decline. Management emphasized active regulatory engagement, continued data generation (4‑year AMT‑130 analysis) and pursuit of ex‑U.S. pathways and early access options, while acknowledging material uncertainty around Phase III design, cost and feasibility.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$32.00
▲(86.48% Upside)
Technical Analysis
Ownership Overview
2.53% Insiders
22.06% Mutual Funds
49.55% Other Institutional Investors
17.59% Public Companies and Individual Investors